Xbrane Biopharma AB
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Xbrane Biopharma AB
Xbrane Refiles Ranibizumab With US FDA
Xbrane has resubmitted its filing for a ranibizumab biosimilar version of Lucentis to the FDA, suggesting that it could receive approval in the first half of next year.
Stada, Biogen Bring Greater Ranibizumab Competition To EU And UK
April brings news of further biosimilar competition to Lucentis in major European markets.
Xbrane Eyes Positive Cash Flow In 2024 – But Out-Licensing Oncology Key
Xbrane has spelled out ambitious cash goals beginning next year, which hinge largely on it finding a partner for its pre-clinical oncology candidates, as it continues to shoulder heavy development and regulatory costs for its suite of biosimilars.
Stada And Xbrane Receive MHRA Nod For Ranibizumab
Stada and Xbrane have celebrated the approval by the UK’s MHRA of the pair’s Ximluci ranibizumab biosimilar rival to Lucentis in Great Britain. A launch is planned this year.
- Generic Drugs
- Large Molecule
- Other Names / Subsidiaries
- Primm Pharma Srl
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.